#inhibitors — Public Fediverse posts

#DISCOVERY #AND #DEVELOPMENT OF #NON #NUCLEOSIDE #REVERSE #TRANSCRIPTASE #INHIBITORS
aepiot.com?q=DISCOVERY%...
#ROBERT #BOSCH JR
search.brave.com/ask?q=Analyz...
#BIG #THREE #TENNIS
aepiot.ro/search.html?...
#VARIABILITY #HYPOTHESIS
aepiot.com?q=VARIABILIT...
aepiot.com

MultiSearch Tag Explorer

#DISCOVERY #AND #DEVELOPMENT OF #NON #NUCLEOSIDE #REVERSE #TRANSCRIPTASE #INHIBITORS
aepiot.com?q=DISCOVERY%...
#ROBERT #BOSCH JR
search.brave.com/ask?q=Analyz...
#BIG #THREE #TENNIS
aepiot.ro/search.html?...
#VARIABILITY #HYPOTHESIS
aepiot.com?q=VARIABILIT...
aepiot.com

MultiSearch Tag Explorer

#Lassa fever and Argentine hemorrhagic fever #treatment in guinea pigs using broad-spectrum cap-dependent #endonuclease #inhibitors, https://etidiohnew.blogspot.com/2026/08/lassa-fever-and-argentine-hemorrhagic.html

#Lassa fever and Argentine hemorrhagic fever #treatment in guinea pigs using broad-spectrum cap-dependent #endonuclease #inhibitors, https://etidiohnew.blogspot.com/2026/08/lassa-fever-and-argentine-hemorrhagic.html

#Lassa fever and Argentine hemorrhagic fever #treatment in guinea pigs using broad-spectrum cap-dependent #endonuclease #inhibitors, https://etidiohnew.blogspot.com/2026/08/lassa-fever-and-argentine-hemorrhagic.html

#Lassa fever and Argentine hemorrhagic fever #treatment in guinea pigs using broad-spectrum cap-dependent #endonuclease #inhibitors, https://etidiohnew.blogspot.com/2026/08/lassa-fever-and-argentine-hemorrhagic.html

#Lassa fever and Argentine hemorrhagic fever #treatment in guinea pigs using broad-spectrum cap-dependent #endonuclease #inhibitors, https://etidiohnew.blogspot.com/2026/08/lassa-fever-and-argentine-hemorrhagic.html

FDA approves new kind of cholesterol pill

https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-pcsk9-inhibitor-lower-ldl-cholesterol-adults-high-cholesterol

Comments: https://news.ycombinator.com/item?id=48964536

#HackerNews #FDA #approval #cholesterol #health #news #PCSK9 #inhibitors #medication

FDA approves new kind of cholesterol pill

https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-pcsk9-inhibitor-lower-ldl-cholesterol-adults-high-cholesterol

Comments: https://news.ycombinator.com/item?id=48964536

#HackerNews #FDA #approval #cholesterol #health #news #PCSK9 #inhibitors #medication

FDA approves new kind of cholesterol pill

https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-pcsk9-inhibitor-lower-ldl-cholesterol-adults-high-cholesterol

Comments: https://news.ycombinator.com/item?id=48964536

#HackerNews #FDA #approval #cholesterol #health #news #PCSK9 #inhibitors #medication

FDA approves new kind of cholesterol pill

https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-pcsk9-inhibitor-lower-ldl-cholesterol-adults-high-cholesterol

Comments: https://news.ycombinator.com/item?id=48964536

#HackerNews #FDA #approval #cholesterol #health #news #PCSK9 #inhibitors #medication

FDA approves new kind of cholesterol pill

https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-pcsk9-inhibitor-lower-ldl-cholesterol-adults-high-cholesterol

Comments: https://news.ycombinator.com/item?id=48964536

#HackerNews #FDA #approval #cholesterol #health #news #PCSK9 #inhibitors #medication

https://www.europesays.com/dk/116967/ Novo Nordisk to showcase new data across its hemophilia portfolio at the ISTH Congress 2026, featuring investigational denecimig #Hemophilia #HemophiliaA #inhibitors #NovoNordisk #OralPresentation #PosterPresentation #prophylaxis #RareBloodDisorders

https://www.europesays.com/ie/529935/ U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need #Éire #FactorVIIIDeficiency #Health #HealthCare #Healthcare #Hemophilia #HYMPAVZI #IE #inhibitors #Ireland #PediatricPatients #PfizerInc #Prophylaxis #SubcutaneousAdministration #TreatmentOptions

What is not clearly seen doesn’t drive our potential customers where we want them.

#startup #companywebsite #business #customeracquisition #customerbehavior #biochemistry #medicine #inhibitors #science #labwork #proteins #drugtrial #aidrugdiscovery #aimedicine

-----

Sign-up link: https://Newsletter.AndrewLipski.com/

Short observations about Websites, Apps, Digital Communication, sometimes short Tech News comments.

Mostly emails under 2 min. read, usually once a week.

What is not clearly seen doesn’t drive our potential customers where we want them.

#startup #companywebsite #business #customeracquisition #customerbehavior #biochemistry #medicine #inhibitors #science #labwork #proteins #drugtrial #aidrugdiscovery #aimedicine

-----

Sign-up link: https://Newsletter.AndrewLipski.com/

Short observations about Websites, Apps, Digital Communication, sometimes short Tech News comments.

Mostly emails under 2 min. read, usually once a week.

What is not clearly seen doesn’t drive our potential customers where we want them.

#startup #companywebsite #business #customeracquisition #customerbehavior #biochemistry #medicine #inhibitors #science #labwork #proteins #drugtrial #aidrugdiscovery #aimedicine

-----

Sign-up link: https://Newsletter.AndrewLipski.com/

Short observations about Websites, Apps, Digital Communication, sometimes short Tech News comments.

Mostly emails under 2 min. read, usually once a week.

What is not clearly seen doesn’t drive our potential customers where we want them.

#startup #companywebsite #business #customeracquisition #customerbehavior #biochemistry #medicine #inhibitors #science #labwork #proteins #drugtrial #aidrugdiscovery #aimedicine

-----

Sign-up link: https://Newsletter.AndrewLipski.com/

Short observations about Websites, Apps, Digital Communication, sometimes short Tech News comments.

Mostly emails under 2 min. read, usually once a week.

European Commission Approves Pfizer’s HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B With Inhibitors

Approval in patients ages 12 and older based on Phase 3 data demonstrating superior bleed reduction to on-demand…
#Europe #EU #EuropeanCommission #factorVIII #FVIII #hemophilia #HYMPAVZI #inhibitors #PfizerInc
https://www.europesays.com/europe/45612/

European Commission Approves Pfizer’s HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B With Inhibitors

Approval in patients ages 12 and older based on Phase 3 data demonstrating superior bleed reduction to on-demand…
#Europe #EU #European #factorVIII #FVIII #hemophilia #HYMPAVZI #inhibitors #PfizerInc
https://www.europesays.com/europe/40680/

Next-generation #inhibitors of #SARS-CoV-2 #Mpro overcome the deficiencies of #Paxlovid, https://etidiohnew.blogspot.com/2026/04/next-generation-inhibitors-of-sars-cov.html

Next-generation #inhibitors of #SARS-CoV-2 #Mpro overcome the deficiencies of #Paxlovid, https://etidiohnew.blogspot.com/2026/04/next-generation-inhibitors-of-sars-cov.html

Next-generation #inhibitors of #SARS-CoV-2 #Mpro overcome the deficiencies of #Paxlovid, https://etidiohnew.blogspot.com/2026/04/next-generation-inhibitors-of-sars-cov.html

Next-generation #inhibitors of #SARS-CoV-2 #Mpro overcome the deficiencies of #Paxlovid, https://etidiohnew.blogspot.com/2026/04/next-generation-inhibitors-of-sars-cov.html

Next-generation #inhibitors of #SARS-CoV-2 #Mpro overcome the deficiencies of #Paxlovid, https://etidiohnew.blogspot.com/2026/04/next-generation-inhibitors-of-sars-cov.html

https://www.europesays.com/ch/39562/ Excellergy to be acquired by Novartis for up to USD 2 billion to advance potentially first-in-class trifunctional effector cell response inhibitors #2 #acquired #advance #be #billion #by #Cell #effector #Excellergy #FirstInClass #for #inhibitors #Novartis #potentially #response #to #trifunctional #Up #usd

#Oseltamivir aziridines are potent #influenza #neuraminidase #inhibitors and imaging agents, https://etidiohnew.blogspot.com/2026/03/oseltamivir-aziridines-are-potent.html

#Oseltamivir aziridines are potent #influenza #neuraminidase #inhibitors and imaging agents, https://etidiohnew.blogspot.com/2026/03/oseltamivir-aziridines-are-potent.html

#Oseltamivir aziridines are potent #influenza #neuraminidase #inhibitors and imaging agents, https://etidiohnew.blogspot.com/2026/03/oseltamivir-aziridines-are-potent.html

#Oseltamivir aziridines are potent #influenza #neuraminidase #inhibitors and imaging agents, https://etidiohnew.blogspot.com/2026/03/oseltamivir-aziridines-are-potent.html

#Oseltamivir aziridines are potent #influenza #neuraminidase #inhibitors and imaging agents, https://etidiohnew.blogspot.com/2026/03/oseltamivir-aziridines-are-potent.html

When the immune system detects a protein from a pathogen,
it’s supposed to dispatch killer T cells to eliminate the invader.

Some cancers can interfere with this process by hijacking the checkpoint proteins that keep our immune system from revving out of control
and using them to turn T cells off.

Starting in the mid-1990s, several research teams found success by treating mice with #checkpoint #inhibitors,
-- then a new class of drugs designed to keep tumor cells from concealing their identity and signaling, effectively, “nothing to see here.”

Thirty years on, checkpoint inhibitors have become a transformative tool in cancer treatment, especially for melanoma.

The research that went into developing checkpoint inhibitors showed conclusively that immune cells detect cancer much in the same way they identify other pathogens:

through differences in protein structure determined by DNA
—a crucial insight.

But as revolutionary as checkpoint inhibitors have been for immunotherapy, they don’t work for everyone
—far from it.

Some 80 percent of patients do not respond to this class of drugs.

Researchers are still trying to understand all the mechanisms that play a role in determining who does respond,
but one key factor is whether the immune system is able to recognize tumor cells on the basis of their mutations.

This is where mRNA vaccines come in.

#Jason #Luke, a melanoma researcher who now serves as chief medical officer of mRNA-medicine start-up #Strand #Therapeutics,
helped to design several ongoing clinical trials of mRNA vaccines for cancer.

He explains that both checkpoint inhibitors and mRNA vaccines build on our deep evolutionary adaptation for fighting pathogens
by identifying the proteins they shed in our bodies.

But checkpoint inhibitors are effective only if the patient’s immune system recognizes the cancer as a threat.

In contrast, mRNA vaccines have the potential to work even in patients whose cancers haven’t spurred much immune response.

The trick, Luke says, is using computational tools to decipher which of a given tumor’s mutations are most likely to be found by the immune system.

#MichaelMemoli
#WilliamColey #immunotherapy #stroma #MHC

When the immune system detects a protein from a pathogen,
it’s supposed to dispatch killer T cells to eliminate the invader.

Some cancers can interfere with this process by hijacking the checkpoint proteins that keep our immune system from revving out of control
and using them to turn T cells off.

Starting in the mid-1990s, several research teams found success by treating mice with #checkpoint #inhibitors,
-- then a new class of drugs designed to keep tumor cells from concealing their identity and signaling, effectively, “nothing to see here.”

Thirty years on, checkpoint inhibitors have become a transformative tool in cancer treatment, especially for melanoma.

The research that went into developing checkpoint inhibitors showed conclusively that immune cells detect cancer much in the same way they identify other pathogens:

through differences in protein structure determined by DNA
—a crucial insight.

But as revolutionary as checkpoint inhibitors have been for immunotherapy, they don’t work for everyone
—far from it.

Some 80 percent of patients do not respond to this class of drugs.

Researchers are still trying to understand all the mechanisms that play a role in determining who does respond,
but one key factor is whether the immune system is able to recognize tumor cells on the basis of their mutations.

This is where mRNA vaccines come in.

#Jason #Luke, a melanoma researcher who now serves as chief medical officer of mRNA-medicine start-up #Strand #Therapeutics,
helped to design several ongoing clinical trials of mRNA vaccines for cancer.

He explains that both checkpoint inhibitors and mRNA vaccines build on our deep evolutionary adaptation for fighting pathogens
by identifying the proteins they shed in our bodies.

But checkpoint inhibitors are effective only if the patient’s immune system recognizes the cancer as a threat.

In contrast, mRNA vaccines have the potential to work even in patients whose cancers haven’t spurred much immune response.

The trick, Luke says, is using computational tools to decipher which of a given tumor’s mutations are most likely to be found by the immune system.

#MichaelMemoli
#WilliamColey #immunotherapy #stroma #MHC

When the immune system detects a protein from a pathogen,
it’s supposed to dispatch killer T cells to eliminate the invader.

Some cancers can interfere with this process by hijacking the checkpoint proteins that keep our immune system from revving out of control
and using them to turn T cells off.

Starting in the mid-1990s, several research teams found success by treating mice with #checkpoint #inhibitors,
-- then a new class of drugs designed to keep tumor cells from concealing their identity and signaling, effectively, “nothing to see here.”

Thirty years on, checkpoint inhibitors have become a transformative tool in cancer treatment, especially for melanoma.

The research that went into developing checkpoint inhibitors showed conclusively that immune cells detect cancer much in the same way they identify other pathogens:

through differences in protein structure determined by DNA
—a crucial insight.

But as revolutionary as checkpoint inhibitors have been for immunotherapy, they don’t work for everyone
—far from it.

Some 80 percent of patients do not respond to this class of drugs.

Researchers are still trying to understand all the mechanisms that play a role in determining who does respond,
but one key factor is whether the immune system is able to recognize tumor cells on the basis of their mutations.

This is where mRNA vaccines come in.

#Jason #Luke, a melanoma researcher who now serves as chief medical officer of mRNA-medicine start-up #Strand #Therapeutics,
helped to design several ongoing clinical trials of mRNA vaccines for cancer.

He explains that both checkpoint inhibitors and mRNA vaccines build on our deep evolutionary adaptation for fighting pathogens
by identifying the proteins they shed in our bodies.

But checkpoint inhibitors are effective only if the patient’s immune system recognizes the cancer as a threat.

In contrast, mRNA vaccines have the potential to work even in patients whose cancers haven’t spurred much immune response.

The trick, Luke says, is using computational tools to decipher which of a given tumor’s mutations are most likely to be found by the immune system.

#MichaelMemoli
#WilliamColey #immunotherapy #stroma #MHC

When the immune system detects a protein from a pathogen,
it’s supposed to dispatch killer T cells to eliminate the invader.

Some cancers can interfere with this process by hijacking the checkpoint proteins that keep our immune system from revving out of control
and using them to turn T cells off.

Starting in the mid-1990s, several research teams found success by treating mice with #checkpoint #inhibitors,
-- then a new class of drugs designed to keep tumor cells from concealing their identity and signaling, effectively, “nothing to see here.”

Thirty years on, checkpoint inhibitors have become a transformative tool in cancer treatment, especially for melanoma.

The research that went into developing checkpoint inhibitors showed conclusively that immune cells detect cancer much in the same way they identify other pathogens:

through differences in protein structure determined by DNA
—a crucial insight.

But as revolutionary as checkpoint inhibitors have been for immunotherapy, they don’t work for everyone
—far from it.

Some 80 percent of patients do not respond to this class of drugs.

Researchers are still trying to understand all the mechanisms that play a role in determining who does respond,
but one key factor is whether the immune system is able to recognize tumor cells on the basis of their mutations.

This is where mRNA vaccines come in.

#Jason #Luke, a melanoma researcher who now serves as chief medical officer of mRNA-medicine start-up #Strand #Therapeutics,
helped to design several ongoing clinical trials of mRNA vaccines for cancer.

He explains that both checkpoint inhibitors and mRNA vaccines build on our deep evolutionary adaptation for fighting pathogens
by identifying the proteins they shed in our bodies.

But checkpoint inhibitors are effective only if the patient’s immune system recognizes the cancer as a threat.

In contrast, mRNA vaccines have the potential to work even in patients whose cancers haven’t spurred much immune response.

The trick, Luke says, is using computational tools to decipher which of a given tumor’s mutations are most likely to be found by the immune system.

#MichaelMemoli
#WilliamColey #immunotherapy #stroma #MHC

When the immune system detects a protein from a pathogen,
it’s supposed to dispatch killer T cells to eliminate the invader.

Some cancers can interfere with this process by hijacking the checkpoint proteins that keep our immune system from revving out of control
and using them to turn T cells off.

Starting in the mid-1990s, several research teams found success by treating mice with #checkpoint #inhibitors,
-- then a new class of drugs designed to keep tumor cells from concealing their identity and signaling, effectively, “nothing to see here.”

Thirty years on, checkpoint inhibitors have become a transformative tool in cancer treatment, especially for melanoma.

The research that went into developing checkpoint inhibitors showed conclusively that immune cells detect cancer much in the same way they identify other pathogens:

through differences in protein structure determined by DNA
—a crucial insight.

But as revolutionary as checkpoint inhibitors have been for immunotherapy, they don’t work for everyone
—far from it.

Some 80 percent of patients do not respond to this class of drugs.

Researchers are still trying to understand all the mechanisms that play a role in determining who does respond,
but one key factor is whether the immune system is able to recognize tumor cells on the basis of their mutations.

This is where mRNA vaccines come in.

#Jason #Luke, a melanoma researcher who now serves as chief medical officer of mRNA-medicine start-up #Strand #Therapeutics,
helped to design several ongoing clinical trials of mRNA vaccines for cancer.

He explains that both checkpoint inhibitors and mRNA vaccines build on our deep evolutionary adaptation for fighting pathogens
by identifying the proteins they shed in our bodies.

But checkpoint inhibitors are effective only if the patient’s immune system recognizes the cancer as a threat.

In contrast, mRNA vaccines have the potential to work even in patients whose cancers haven’t spurred much immune response.

The trick, Luke says, is using computational tools to decipher which of a given tumor’s mutations are most likely to be found by the immune system.

#MichaelMemoli
#WilliamColey #immunotherapy #stroma #MHC

#Global #update on susceptibilities of #influenza viruses to #neuraminidase #inhibitors and the cap-dependent endonuclease inhibitor #baloxavir, 2020–2023, https://etidiohnew.blogspot.com/2025/06/global-update-on-susceptibilities-of.html

#Global #update on susceptibilities of #influenza viruses to #neuraminidase #inhibitors and the cap-dependent endonuclease inhibitor #baloxavir, 2020–2023, https://etidiohnew.blogspot.com/2025/06/global-update-on-susceptibilities-of.html

#Global #update on susceptibilities of #influenza viruses to #neuraminidase #inhibitors and the cap-dependent endonuclease inhibitor #baloxavir, 2020–2023, https://etidiohnew.blogspot.com/2025/06/global-update-on-susceptibilities-of.html

#Global #update on susceptibilities of #influenza viruses to #neuraminidase #inhibitors and the cap-dependent endonuclease inhibitor #baloxavir, 2020–2023, https://etidiohnew.blogspot.com/2025/06/global-update-on-susceptibilities-of.html

#Global #update on susceptibilities of #influenza viruses to #neuraminidase #inhibitors and the cap-dependent endonuclease inhibitor #baloxavir, 2020–2023, https://etidiohnew.blogspot.com/2025/06/global-update-on-susceptibilities-of.html

Effects of #JAK #inhibitors in adults admitted to #hospital due to #COVID19: a systematic review and individual participant data meta-analysis of randomised clinical trials, https://etidiohnew.blogspot.com/2025/05/effects-of-jak-inhibitors-in-adults.html

Effects of #JAK #inhibitors in adults admitted to #hospital due to #COVID19: a systematic review and individual participant data meta-analysis of randomised clinical trials, https://etidiohnew.blogspot.com/2025/05/effects-of-jak-inhibitors-in-adults.html

Effects of #JAK #inhibitors in adults admitted to #hospital due to #COVID19: a systematic review and individual participant data meta-analysis of randomised clinical trials, https://etidiohnew.blogspot.com/2025/05/effects-of-jak-inhibitors-in-adults.html

Effects of #JAK #inhibitors in adults admitted to #hospital due to #COVID19: a systematic review and individual participant data meta-analysis of randomised clinical trials, https://etidiohnew.blogspot.com/2025/05/effects-of-jak-inhibitors-in-adults.html

Effects of #JAK #inhibitors in adults admitted to #hospital due to #COVID19: a systematic review and individual participant data meta-analysis of randomised clinical trials, https://etidiohnew.blogspot.com/2025/05/effects-of-jak-inhibitors-in-adults.html

SciTech Chronicles. . . . . .May 6th, 2025

https://bit.ly/stc050625

#EphB1/2 #tyrosine #kinase #inhibitors #carbene #thiamine #Breslow #B1 #3D-printable #electroencephalogram #continuously #bioadhesive #AMT #mesothelioma #"low-carbon metal oxides" #CO2 #"digital twin" #"3D digital model" #sonar #Magellan

Great keynote lecture by Marta Artola of the @LED3hub at #Lunteren. She talked about the importance of glycosidases in various diseases and her great work on conformationally locked #covalent and non-covalent #inhibitors and #probes.
#chemistry #ChemBio
https://pubs.acs.org/doi/10.1021/jacs.2c05666

Great keynote lecture by Marta Artola of the @LED3hub at #Lunteren. She talked about the importance of glycosidases in various diseases and her great work on conformationally locked #covalent and non-covalent #inhibitors and #probes.
#chemistry #ChemBio
https://pubs.acs.org/doi/10.1021/jacs.2c05666

Great keynote lecture by Marta Artola of the @LED3hub at #Lunteren. She talked about the importance of glycosidases in various diseases and her great work on conformationally locked #covalent and non-covalent #inhibitors and #probes.
#chemistry #ChemBio
https://pubs.acs.org/doi/10.1021/jacs.2c05666

#Structural and #virologic #mechanism of the emergence of #resistance to #Mpro #inhibitors in #SARS-CoV-2, PNAS: https://www.pnas.org/doi/abs/10.1073/pnas.2404175121?af=R

We generated SARS-CoV-2 variants resistant to three SARS-CoV-2 main protease (Mpro) inhibitors (#nirmatrelvir, TKB245, and 5h), by propagating the ancestral SARS-CoV-2WK521WT in VeroE6TMPRSS2 cells with increasing concentrations of each inhibitor and examined their structural and virologic profiles.

#Structural and #virologic #mechanism of the emergence of #resistance to #Mpro #inhibitors in #SARS-CoV-2, PNAS: https://www.pnas.org/doi/abs/10.1073/pnas.2404175121?af=R

We generated SARS-CoV-2 variants resistant to three SARS-CoV-2 main protease (Mpro) inhibitors (#nirmatrelvir, TKB245, and 5h), by propagating the ancestral SARS-CoV-2WK521WT in VeroE6TMPRSS2 cells with increasing concentrations of each inhibitor and examined their structural and virologic profiles.

#Structural and #virologic #mechanism of the emergence of #resistance to #Mpro #inhibitors in #SARS-CoV-2, PNAS: https://www.pnas.org/doi/abs/10.1073/pnas.2404175121?af=R

We generated SARS-CoV-2 variants resistant to three SARS-CoV-2 main protease (Mpro) inhibitors (#nirmatrelvir, TKB245, and 5h), by propagating the ancestral SARS-CoV-2WK521WT in VeroE6TMPRSS2 cells with increasing concentrations of each inhibitor and examined their structural and virologic profiles.

#Structural and #virologic #mechanism of the emergence of #resistance to #Mpro #inhibitors in #SARS-CoV-2, PNAS: https://www.pnas.org/doi/abs/10.1073/pnas.2404175121?af=R

We generated SARS-CoV-2 variants resistant to three SARS-CoV-2 main protease (Mpro) inhibitors (#nirmatrelvir, TKB245, and 5h), by propagating the ancestral SARS-CoV-2WK521WT in VeroE6TMPRSS2 cells with increasing concentrations of each inhibitor and examined their structural and virologic profiles.

#Structural and #virologic #mechanism of the emergence of #resistance to #Mpro #inhibitors in #SARS-CoV-2, PNAS: https://www.pnas.org/doi/abs/10.1073/pnas.2404175121?af=R

We generated SARS-CoV-2 variants resistant to three SARS-CoV-2 main protease (Mpro) inhibitors (#nirmatrelvir, TKB245, and 5h), by propagating the ancestral SARS-CoV-2WK521WT in VeroE6TMPRSS2 cells with increasing concentrations of each inhibitor and examined their structural and virologic profiles.